[1]
|
Saleh, K., Khalifeh-Saleh, N. and Kourie, H.R. (2020) Acute Myeloid Leukemia Transformed to a Targetable Disease. Future Oncology (London, England), 16, 961-972. https://doi.org/10.2217/fon-2019-0670
|
[2]
|
DeSantis, C.E., Lin, C.C., Mariotto, A.B., Siegel, R.L., Stein, K.D., Kramer, J.L., Alteri, R., Robbins, A.S. and Jemal, A. (2014) Cancer Treatment and Survivorship Statistics, 2014. CA: A Cancer Journal for Clinicians, 64, 252-271.
https://doi.org/10.3322/caac.21235
|
[3]
|
Shallis, R.M., Wang, R., Davidoff, A., Ma, X. and Zeidan, A.M. (2019) Epidemiology of Acute Myeloid Leukemia: Recent Progress and Enduring Challenges. Blood Reviews, 36, 70-87. https://doi.org/10.1016/j.blre.2019.04.005
|
[4]
|
Daver, N., Schlenk, R.F., Russell, N.H. and Levis, M.J. (2019) Targeting FLT3 Mutations in AML: Review of Current Knowledge and Evidence. Leukemia, 33, 299-312. https://doi.org/10.1038/s41375-018-0357-9
|
[5]
|
Megías-Vericat, J.E., Ballesta-López, O., Barragán, E., Mar-tínez-Cuadrón, D. and Montesinos, P. (2020) Tyrosine Kinase Inhibitors for Acute Myeloid Leukemia: A Step toward Disease Control? Blood Reviews, 44, Article ID: 100675.
https://doi.org/10.1016/j.blre.2020.100675
|
[6]
|
McLean, C.M., Karemaker, I.D. and van Leeuwen, F. (2014) The Emerging Roles of DOT1L in Leukemia and Normal Development. Leukemia, 28, 2131-2138. https://doi.org/10.1038/leu.2014.169
|
[7]
|
Stein, E.M., Garcia-Manero, G., Rizzieri, D.A., Tibes, R., Berdeja, J.G., Savona, M.R., Jongen-Lavrenic, M., Altman, J.K., Thomson, B., Blakemore, S.J., Daigle, S.R., Waters, N.J., Suttle, A.B., Clawson, A., Pollock, R., Krivtsov, A., Armstrong, S.A., DiMartino,J., Hedrick, E., Löwenberg, B. and Tallman, M.S. (2018) The DOT1L Inhibitor Pinometostat Reduces H3K79 Methylation and Has Modest Clinical Activity in Adult Acute Leukemia. Blood, 131, 2661-2669. https://doi.org/10.1182/blood-2017-12-818948
|
[8]
|
Assi, R., Kantarjian, H., Ravandi, F. and Daver, N. (2018) Immune Therapies in Acute Myeloid Leukemia: A Focus on Monoclonal Antibod-ies and Immune Checkpoint Inhibitors. Current Opinion in Hematology, 25, 136-145.
https://doi.org/10.1097/MOH.0000000000000401
|
[9]
|
Clark, M.C. and Stein, A. (2020) CD33 Directed Bispecific Antibodies in Acute Myeloid Leukemia. Best Practice & Research. Clinical Haematology, 33, Article ID: 101224. https://doi.org/10.1016/j.beha.2020.101224
|
[10]
|
Sikic, B.I., Lakhani, N., Patnaik, A., Shah, S.A., Chandana, S.R., Rasco, D., Colevas, A.D., O’Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G.A., Villalobos, V., Prohaska, S.S., Howard, M., Beeram, M., Chao, M.P., Agoram, B., Chen, J.Y., Huang, J., Axt, M. and Padda, S.K. (2019) First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients with Advanced Cancers. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 37, 946-953. https://doi.org/10.1200/JCO.18.02018
|
[11]
|
Riether, C., Pabst, T., Höpner, S., Bacher, U., Hinterbrandner, M., Banz, Y., Müller, R., Manz, M.G., Gharib, W.H., Francisco, D., Bruggmann, R., van Rompaey, L., Moshir, M., De-lahaye, T., Gandini, D., Erzeel, E., Hultberg, A., Fung, S., de Haard, H., Leupin, N. and Ochsenbein, A.F. (2020) Tar-geting CD70 with Cusatuzumab Eliminates Acute Myeloid Leukemia Stem Cells in Patients Treated with Hypomethylat-ing Agents. Nature Medicine, 26, 1459-1467.
https://doi.org/10.1038/s41591-020-0910-8
|
[12]
|
Schiller, G.J. (2014) Evolving Treatment Strategies in Patients with High-Risk Acute Myeloid Leukemia. Leukemia & Lymphoma, 55, 2438-2448. https://doi.org/10.3109/10428194.2014.881479
|
[13]
|
Daver, N., Alotaibi, A.S., Bücklein, V. and Subklewe, M. (2021) T-Cell-Based Immunotherapy of Acute Myeloid Leukemia: Current Concepts and Future Developments. Leuke-mia, 35, 1843-1863.
https://doi.org/10.1038/s41375-021-01253-x
|
[14]
|
Maziarz, R.T., Scott, B.L., Mohan, S.R., et al. (2016) A Phase II, Randomized Trial of Standard of Care with or without Midostaurin to Prevent Relapse Following Allogeneic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia. Journal of Clinical Oncology, 33.
https://doi.org/10.1200/jco.2015.33.15_suppl.tps7094
|
[15]
|
Ma, J., Zhao, S., Qiao, X., Knight, T., Edwards, H., Polin, L., Kushner, J., Dzinic, S.H., White, K., Wang, G., Zhao, L., Lin, H., Wang, Y., Taub, J.W. and Ge, Y. (2019) In-hibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 25, 6815-6826.
https://doi.org/10.1158/1078-0432.CCR-19-0832
|
[16]
|
Ravandi, F., Arana Yi, C., Cortes, J.E., Levis, M., Faderl, S., Garcia-Manero, G., Jabbour, E., Konopleva, M., O’Brien, S., Estrov, Z., Borthakur, G., Thomas, D., Pierce, S., Brandt, M., Pratz, K., Luthra, R., Andreeff, M. and Kantarjian, H. (2014) Final Report of Phase II Study of Sorafenib, Cytarabine and Idarubicin for Initial Therapy in Younger Patients with Acute Myeloid Leukemia. Leukemia, 28, 1543-1545. https://doi.org/10.1038/leu.2014.54
|
[17]
|
Inaba, H., Rubnitz, J.E., Coustan-Smith, E., Li, L., Furmanski, B.D., Mascara, G.P., Heym, K.M., Christensen, R., Onciu, M., Shurtleff, S.A., Pounds, S.B., Pui, C.H., Ribeiro, R.C., Cam-pana, D. and Baker, S.D. (2011) Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor So-rafenib in Combination with Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29, 3293-3300. https://doi.org/10.1200/JCO.2011.34.7427
|
[18]
|
Röllig, C., Serve, H., Hüttmann, A., Noppeney, R., Müller-Tidow, C., Krug, U., Baldus, C.D., Brandts, C.H., Kunzmann, V., Einsele, H., Krämer, A., Schäfer-Eckart, K., Neubauer, A., Burchert, A., Giagounidis, A., Krause, S.W., Mackensen, A., Aulitzky, W., Herbst, R., Hänel, M. and Study Alliance Leukaemia (2015) Addition of Sorafenib Versus Placebo to Standard Therapy in Patients Aged 60 Years or Younger with Newly Diagnosed Acute Myeloid Leukaemia (SORAML): A Multicentre, Phase 2, Randomised Controlled Trial. The Lancet. Oncology, 16, 1691-1699.
https://doi.org/10.1016/S1470-2045(15)00362-9
|
[19]
|
Serve, H., Krug, U., Wagner, R., Sauerland, M.C., Heinecke, A., Brunnberg, U., Schaich, M., Ottmann, O., Duyster, J., Wandt, H., Fischer, T., Giagounidis, A., Neubauer, A., Reichle, A., Aulitzky, W., Noppeney, R., Blau, I., Kunzmann, V., Stuhlmann, R., Krämer, A. and Berdel, W.E. (2013) Sorafenib in Combination with Intensive Chemotherapy in Elderly Patients with Acute Myeloid Leukemia: Results from a Randomized, Placebo-Controlled Trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31, 3110-3118.
https://doi.org/10.1200/JCO.2012.46.4990
|
[20]
|
Garcia-Manero, G., Gore, S.D., Cogle, C., Ward, R., Shi, T., Macbeth, K.J., Laille, E., Giordano, H., Sakoian, S., Jabbour, E., Kantarjian, H. and Skikne, B. (2011) Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29, 2521-2527. https://doi.org/10.1200/JCO.2010.34.4226
|
[21]
|
Wei, A.H., Döhner, H., Pocock, C., Montesinos, P., Afanasyev, B., Dombret, H., Ravandi, F., Sayar, H., Jang, J.H., Porkka, K., Selleslag, D., Sandhu, I., Turgut, M., Giai, V., Ofran, Y., Kizil Çakar, M., Botelho de Sousa, A., Rybka, J., Frairia, C., Borin, L. and QUAZAR AML-001 Trial Investigators (2020) Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. The New England Jour-nal of Medicine, 383, 2526-2537.
https://doi.org/10.1056/NEJMoa2004444
|
[22]
|
Baragaño Raneros, A., Martín-Palanco, V., Fernandez, A.F., Ro-driguez, R.M., Fraga, M.F., Lopez-Larrea, C. and Suarez-Alvarez, B. (2015) Methylation of NKG2D Ligands Contrib-utes to Immune System Evasion in Acute Myeloid Leukemia. Genes and Immunity, 16, 71-82. https://doi.org/10.1038/gene.2014.58
|
[23]
|
Perl, A.E., Altman, J.K., Cortes, J., Smith, C., Litzow, M., Baer, M.R., Claxton, D., Erba, H.P., Gill, S., Goldberg, S., Jurcic, J.G., Larson, R.A., Liu, C., Ritchie, E., Schiller, G., Spira, A.I., Strickland, S.A., Tibes, R., Ustun, C., Wang, E.S. and Levis, M. (2017) Selective Inhibition of FLT3 by Gilteritinib in Relapsed or Refractory Acute Myeloid Leukaemia: A Multicentre, First-in-Human, Open-Label, Phase 1-2 Study. The Lancet. Oncology, 18, 1061-1075.
https://doi.org/10.1016/S1470-2045(17)30416-3
|
[24]
|
Park, I.K., Mundy-Bosse, B., Whitman, S.P., Zhang, X., Warner, S.L., Bearss, D.J., Blum, W., Marcucci, G. and Caligiuri, M.A. (2015) Receptor Tyrosine Kinase Axl Is Re-quired for Resistance of Leukemic Cells to FLT3-Targeted Therapy in Acute Myeloid Leukemia. Leukemia, 29, 2382-2389. https://doi.org/10.1038/leu.2015.147
|
[25]
|
Stone, R.M., Mandrekar, S.J., Sanford, B.L., Laumann, K., Geyer, S., Bloomfield, C.D., Thiede, C., Prior, T.W., Döhner, K., Marcucci, G., Lo-Coco, F., Klisovic, R.B., Wei, A., Sierra, J., Sanz, M.A., Brandwein, J.M., de Witte, T., Niederwieser, D., Appelbaum, F.R., Medeiros, B.C. and Döhner, H. (2017) Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. The New England Journal of Medicine, 377, 454-464.
https://doi.org/10.1056/NEJMoa1614359
|
[26]
|
Ramsingh, G., Westervelt, P., McBride, A., Stockerl-Goldstein, K., Vij, R., Fiala, M., Uy, G., Cashen, A., Dipersio, J.F. and Abboud, C.N. (2014) Phase I Study of Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor (CLAG Regimen) and Midostaurin and All-Trans Retinoic Acid in Re-lapsed/Refractory AML. International Journal of Hematology, 99, 272-278. https://doi.org/10.1007/s12185-014-1503-4
|
[27]
|
Cooper, B.W., Kindwall-Keller, T.L., Craig, M.D., Creger, R.J., Hamadani, M., Tse, W.W. and Lazarus, H.M. (2015) A Phase I Study of Midostaurin and Azacitidine in Relapsed and Elderly AML Patients. Clinical Lymphoma, Myeloma & Leukemia, 15, 428-432.e2. https://doi.org/10.1016/j.clml.2015.02.017
|
[28]
|
Zarrinkar, P.P., Gunawardane, R.N., Cramer, M.D., Gardner, M.F., Brigham, D., Belli, B., Karaman, M.W., Pratz, K.W., Pallares, G., Chao, Q., Sprankle, K.G., Patel, H.K., Levis, M., Armstrong, R.C., James, J. and Bhagwat, S.S. (2009) AC220 Is a Uniquely Potent and Selective Inhibitor of FLT3 for the Treatment of Acute Myeloid Leukemia (AML). Blood, 114, 2984-2992. https://doi.org/10.1182/blood-2009-05-222034
|
[29]
|
Cortes, J.E., Khaled, S., Martinelli, G., Perl, A.E., Ganguly, S., Russell, N., Krämer, A.,Dombret, H., Hogge, D., Jonas, B.A., Leung, A.Y., Mehta, P., Montesinos, P., Radsak, M., Si-ca, S., Arunachalam, M., Holmes, M., Kobayashi, K., Namuyinga, R., Ge, N. and Levis, M.J. (2019) Quizartinib versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukaemia (QuANTUM-R): A Multicentre, Randomised, Controlled, Open-Label, Phase 3 Trial. The Lancet. Oncology, 20, 984-997. https://doi.org/10.1016/S1470-2045(19)30150-0
|
[30]
|
Cortes, J.E., Kantarjian, H., Foran, J.M., Ghirdaladze, D., Zodelava, M., Borthakur, G., Gammon, G., Trone, D., Armstrong, R.C., James, J. and Levis, M. (2013) Phase I Study of Quizartinib Administered Daily to Patients with Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31, 3681-3687. https://doi.org/10.1200/JCO.2013.48.8783
|
[31]
|
Cortes, J.E., Tallman, M.S., Schiller, G., et al. (2013) Results of a Phase 2 Randomized, Open-Label, Study of Lower Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML). Blood, 122, 494. https://doi.org/10.1182/blood.V122.21.494.494
|
[32]
|
Cortes, J., Perl, A.E., Döhner, H., Kantarjian, H., Martinelli, G., Kovacsovics, T., Rousselot, P., Steffen, B., Dombret, H., Estey, E., Strickland, S., Altman, J.K., Baldus, C.D., Burnett, A., Krämer, A., Russell, N., Shah, N.P., Smith, C.C., Wang, E.S., Ifrah, N. and Levis, M. (2018) Quizartinib, an FLT3 Inhibitor, as Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukae-mia: An Open-Label, Multicentre, Single-Arm, Phase 2 Trial. The Lancet. Oncology, 19, 889-903. https://doi.org/10.1016/S1470-2045(18)30240-7
|
[33]
|
Burnett, A.K., Bowen, D., Russell, N., Knapper, S., Milligan, D., Hunter, A.E. and Hills, R.K. (2013) AC220 (Quizartinib) Can Be Safely Combined with Conventional Chemotherapy in Older Patients with Newly Diagnosed Acute Myeloid Leukaemia: Experience from the AML18 Pilot Trial. Blood, 122, 622.
https://doi.org/10.1182/blood.V122.21.622.622
|